NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

MCX Shares Decline 5 Percent Following UBS Downgrade

The Multi Commodity Exchange (MCX) shares experienced a decline of up to 5 percent on Friday, following a downgraded rating from brokerage UBS. The stock reached an intraday low of Rs 3,000 per share on the National Stock Exchange (NSE).

The decline marks the third consecutive trading session in which MCX shares have fallen, with a total decrease of over 9 percent. This drop follows a period of elevated volatility across key commodities, which had previously boosted trading volumes. However, UBS suggests that the peak earnings momentum for MCX is likely behind it.

According to UBS' analysis, the volumes in Q1FY27 remain healthy, but have normalized from the elevated levels seen during Q4FY26. As a result, the brokerage downgraded the stock to "Neutral" from its earlier rating.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Notably, UBS raised the target price for MCX to Rs 3,600 from Rs 3,200, implying an upside potential of 14 percent from the previous closing level. Despite this, the brokerage believes that the stock valuations remain rich at around 50 times one-year forward price-to-earnings, which is approximately 10 percent above the historical average.

RatingPrevious Target PriceNew Target PriceUpside Potential
NeutralRs 3,200Rs 3,60014%

The brokerage concludes that strong volume growth appears to be already priced in, limiting further upside for the stock.

Investor Takeaway

MCX shares may decline further due to slowing earnings momentum.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.